Experimental immune cell therapy for advanced cancers shows early promise but trial halted
NCT ID NCT05729399
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a personalized therapy called GT201, made from a patient's own tumor-fighting immune cells (TILs), for advanced solid tumors. Only 6 people were enrolled before the study was terminated. The treatment involved intensive chemotherapy followed by infusion of the immune cells and a supportive drug. The main goal was to check safety, but the small size and early stop mean we cannot draw firm conclusions about effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
autologous tumor-infiltrating lymphocyte injection (GT201)
What this could lead to
If successful, this approach could point toward a new treatment option for advanced solid tumors using a patient's own immune cells.
What could go wrong
This was a very early, small trial that was terminated early with only 6 participants. The therapy involves intensive chemotherapy and carries risks like severe immune reactions and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450000, China